AI and machine learning
Supports target prioritisation, pattern detection, and decision-making across complex biological data.
Melbourne, Australia
Precision Medicine
Founder-led biotech focused on rare congenital disease (MPS II), integrating multi-omics data, AI/ML, and CRO partnerships to accelerate the development of personalized medicines.
Initiative model
Mucopolysaccharidosis type II (MPS II)
A strategic focus for validating the platform's potential in rare disease.
Core modality
Personalised Therapy
Designed for long-term accessibility, scalability, and personalized therapeutic intent.
AI-driven precision medicine integrating multi-omics data and CRO partnerships for targeted rare disease therapy.
A founder-led platform strategy for high-unmet-need rare diseases
Multi-omics integration
Links diverse biological layers to support mechanistic insight and precision medicine development.
Tailored Personalised Therapy targeting
Designed for transcriptional, enzymatic, and DNA/RNA-related disease mechanisms through personalized therapeutic approaches.
Strategic framework
Built for precision rare disease discovery
A cohesive approach integrating therapeutic focus, validation rigor, and collaborative execution.
MPS II provides a clinically important starting point for SunforestX's rare disease strategy, grounding the platform in a concrete therapeutic challenge while building toward broader rare disease applicability.
Therapeutic precision
Mechanism-focused design targeting pathogenic drivers with computational rigor.
Human-relevant validation
Organ-on-a-chip systems bridge computational insight and clinical translation.
Collaborative execution
Designed to engage clinicians, academia, CROs, and strategic partners.
Parkville-linked positioning
Located within Melbourne's biomedical precinct for ecosystem access.
From data to mechanism to validation
Integrated biomedical and disease data
Mechanism and target prioritisation
Tailored Personalised Therapy strategy
Organ-on-a-chip validation
Program advancement via partners
Building toward a brighter future for children and families affected by rare disease
Rare pediatric disease affects not only biology, but childhood, family life, and long-term wellbeing.
The company vision is grounded in hope, trust, healing, and the search for more accessible therapeutic options.
Current Stage
Founder-led, early-stage, and being built with strategic discipline
SunforestX Therapeutics is currently a founder-led company focused on refining its scientific thesis, translational strategy, and future collaboration model around rare congenital disease therapy development.
What to add next
Replace this section with confirmed founder biography details, real contact information, named collaborators or advisors once formalised, and future program milestones when available.